title: Beyond PSA: managing modern therapeutic options in metastatic castration-resistant prostate cancer.
abstract: Prostate cancer remains a significant cause of cancer-related deaths in men in the United States. Significant advances in the treatment of metastatic castration-resistant prostate cancer have been made in recent years with the arrival of new therapeutic targets and options. The definition of progression of disease must be thought of in the context of clinical symptoms and radiographic evidence rather than as changes in prostate-specific antigen (PSA). Ultimately, the use of PSA criteria alone should not be used to determine the progression of disease; instead, PSA should be evaluated in combination with other clinical data.
authors: From the Medical Oncology Service, National Cancer Institute, Bethesda, Maryland.
authors: Fatima H
authors: FH
authors: Karzai
authors: From the Medical Oncology Service, National Cancer Institute, Bethesda, Maryland.
authors: Ravi A
authors: RA
authors: Madan
authors: From the Medical Oncology Service, National Cancer Institute, Bethesda, Maryland.
authors: William D
authors: WD
authors: Figg
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood*; D018450:Disease Progression; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood*; D064129:Prostatic Neoplasms, Castration-Resistant / Q000097:blood* / Q000188:drug therapy / Q000473:pathology
chemical_list: D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen